US Pharma MarketingAn uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
Aurora Therapeutics, the first bespoke CRISPR startup, lays off staff and drops its PKU program as CEO Ed Kaye exits, months after a $16M seed round. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
Aurora Therapeutics, the first company that focused on creating bespoke gene editing treatments, has laid off several staff members and stopped its lead program.
The company was using CRISPR base editing to fix mutations that ...
Source: Endpoints News